

Susceptibility of *Clostridium difficile* Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators

Jane Freeman,^{a,b} Jonathan Vernon,^b Richard Vickers,^c Mark H. Wilcox^{a,b}

Microbiology, Leeds Teaching Hospitals Trust,^a and Healthcare Associated Infections Research Group, Leeds Institute for Biomedical and Clinical Sciences,^b University of Leeds, Leeds, United Kingdom; Summit Therapeutics, Abingdon, Oxfordshire, United Kingdom^c

We determined the *in vitro* activity of SMT19969 and 11 comparators, including metronidazole, vancomycin, and fidaxomicin, against 107 *C. difficile* isolates of different antimicrobial resistance phenotypes. Fidaxomicin and SMT19969 were the most active. The fidaxomicin and SMT19969 geometric mean MICs were highest in ribotypes known to show multiple resistance. Core-susceptibility to linezolid and moxifloxacin was evident in ribotypes 001, 017, 027, and 356. The high-level ceftriaxone resistance in ribotypes 356 and 018 was location linked.

Clostridium difficile infection (CDI) is a significant cause of nosocomial diarrhea and a continuing burden on health care resources (1). Most antimicrobials have been associated with CDI cases at some point, including the treatment agents vancomycin and metronidazole (*Clostridium difficile* Ribotyping Network [CDRN] for England and Northern Ireland 2011–2013; <https://www.gov.uk/government/publications/clostridium-difficile-ribotyping-network-cdrn-report>). CDI recurrence is common following conventional antimicrobial treatment and is associated with reduced gut bacterial diversity (2). Treatment options remain limited, despite the introduction of fidaxomicin for CDI; therefore, development of novel antimicrobial agents, particularly ones with a lower potential for gut microbiota depletion, is needed. SMT19969 is a novel antimicrobial with potent *in vitro* activity against *C. difficile* (3) but limited activity against gut microflora (4). We investigated the activity of SMT19969 and 11 comparators, including predisposing and treatment agents, against *C. difficile* isolates of different antimicrobial resistance phenotypes.

A panel of 107 *C. difficile* isolates was selected from a collection assembled during the *ClosER* study (5) by permission of Astellas Pharma Europe. Clinical isolates were collected between July 2011 and April 2013 and were selected to maximize the diversity of antimicrobial resistance phenotypes. The susceptibilities of *C. difficile* isolates to metronidazole, vancomycin, fidaxomicin, rifampin, moxifloxacin, clindamycin, imipenem, chloramphenicol, tigecycline, SMT19969, linezolid, and ceftriaxone were determined using a Wilkins-Chalgren agar incorporation method (5, 6). The MIC was defined as the lowest dilution at which growth was completely inhibited or at which only single colonies remained.

The MIC results for each isolate were designated susceptible (S), intermediately resistant (I), fully resistant (R), or reduced susceptibility (RS) according to the breakpoints defined in Table 1. The breakpoints were established according to the Clinical Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST), or published data. Each result was assigned a score (S = 0, I = 1, and R = 2). A cumulative resistance score (CRS), based on susceptibility to each of the 11 antimicrobials tested, was generated for each isolate. Thus, an isolate that was fully susceptible to 6, intermediately

resistant to 2, and resistant to 3 antimicrobials would generate a score of 8 (0 + 0 + 0 + 0 + 0 + 0 + 1 + 1 + 2 + 2 + 2).

Fidaxomicin was the most active agent, followed by SMT19969, with similar geometric mean (GM) MICs (0.04 mg/liter versus 0.07 mg/liter, respectively) (Table 1) and with no evidence of resistance to either agent (Table 1). Fidaxomicin (GM MIC of 0.04 mg/liter) was 10- and 20-fold more active than metronidazole (GM MIC of 0.41 mg/liter) and vancomycin (GM MIC of 0.80 mg/liter), while SMT19969 (GM MIC of 0.07 mg/liter) was 6- and 11-fold more active, respectively. The MICs of both fidaxomicin and SMT19969 were comparable to those observed previously (3, 5, 7, 8). Although the fidaxomicin MICs were slightly higher among the highly related ribotype (RT) 027 ($n = 22$) and RT198 ($n = 8$) isolates (GM MIC of 0.08 mg/liter for both) than for all isolates (0.04 mg/liter), this was not statistically significant (Kruskal-Wallis $P = 0.86$ and 1.00 , respectively). Conversely, the fidaxomicin MICs were statistically significantly lower among RT001 isolates (Kruskal-Wallis $P = 0.0001$), with a GM MIC of 0.01 mg/liter, reflecting previous results (5, 7, 8). The SMT19969 MICs for RT027 (GM = 0.11 mg/liter) and RT017 (GM = 0.12 mg/liter) isolates were slightly elevated above those for all isolates, but this was not statistically significant (Kruskal-Wallis $P = 0.30$ and 0.29 , respectively). Ribotypes 027, 198, and 017 were associated with multiple antimicrobial resistance in a previous study (5). The slightly elevated fidaxomicin and SMT19969 GM MICs observed against selected ribotypes are unlikely to have clinical significance, given the high intraluminal gastrointestinal (GI) concentrations of both agents (9, 10). The GM metronidazole MICs were also slightly higher among RT027 and RT198 (1 mg/liter for both) isolates than those for all isolates (0.4 mg/liter), in line with

Received 19 August 2015 Returned for modification 23 September 2015

Accepted 4 November 2015

Accepted manuscript posted online 9 November 2015

Citation Freeman J, Vernon J, Vickers R, Wilcox MH. 2016. Susceptibility of *Clostridium difficile* isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators. *Antimicrob Agents Chemother* 60:689–692. doi:10.1128/AAC.02000-15.

Address correspondence to Mark H. Wilcox, mark.wilcox@nhs.net.

Copyright © 2015 Freeman et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 Unported license](https://creativecommons.org/licenses/by/4.0/).

TABLE 1 Susceptibility of 107 *C. difficile* isolates to SMT19969 and 11 comparators

Parameter	Results for drug (breakpoint):										
	Fidaxomicin (S < 1; RS > 1 ⁵)	Metronidazole (S < 2; I = 4; R > 8 ⁵)	Vancomycin (S < 2; I = 4; R > 8 ⁵)	Rifampin (S < 0.002; I = 0.003–16; R > 32 ⁵)	Moxifloxacin (S < 2; I = 4; R > 8 ⁵)	Clindamycin (S < 2; I = 4; R > 8 ⁵)	Imipenem (S < 4; I = 8; R > 16 ⁵)	Chloramphenicol (S < 8; I = 16; R > 32 ⁵)	Tigecycline (S < 0.2 ⁵ ; RS > 0.25 ⁵)	Linezolid (S < 4; R > 4 ¹¹)	Ceftriaxone (S < 16; I = 32; R > 64 ¹⁴)
Geometric mean	0.04	0.41	0.80	0.03	9.81	19.00	4.00	5.97	0.04	5.19	58.18
MIC ₅₀	0.06	0.5	1	0.002	16	16	4	4	0.03	4	64
MIC ₉₀	0.125	2	2	32	32	128	8	16	0.06	16	128
Range	0.015–0.5	<0.125–2	0.5–8	<0.001–>32	1–128	2–128	1–16	4–>256	0.03–0.25	2–32	16–>256
%S	100.00	100.00	100.00	70.64	31.19	7.34	73.39	84.40	99.07	85.32	6.42
%I	0.00	0.00	0.00	2.75	0.92	6.42	22.94	11.01	0.93	0.92	33.03
%R	0.00	0.00	0.00	26.61	67.89	86.24	3.67	4.59	0.00	13.76	60.55

previous observations (5, 8). However, despite low gut concentrations, metronidazole treatment failure has not been linked to decreased susceptibility to this agent (8).

There was a significant correlation between increased CRS and increased SMT19969 MICs (Pearson’s product-moment correlation $r = 0.33$; $P = 0.004$), metronidazole MICs ($r = 0.27$; $P = 0.004$), and, to a lesser degree, fidaxomicin MICs ($r = 0.25$; $p = 0.01$), but no such correlation for vancomycin ($r = 0.12$; $P = 0.21$). A comparison of susceptibilities by ribotype in this study would inevitably contain bias, given that the selection criteria were based on the resistance phenotypes; however, it is worth noting that the *C. difficile* isolates with the highest MICs of SMT19969 belonged to ribotypes noted for resistance to multiple antimicrobials.

Isolates were selected to represent a broad range of antimicrobial resistance phenotypes. The results for metronidazole, vancomycin, fidaxomicin, rifampin, moxifloxacin, clindamycin, chloramphenicol, and tigecycline largely reflected those previously determined (5), with evidence of high-level resistance to rifampin, moxifloxacin, clindamycin, and chloramphenicol (Table 1). Imipenem resistance was low (3.7%), and reduced susceptibility to tigecycline was very rare (<1%). Most isolates were linezolid susceptible (85.3%), but, unexpectedly, 13.8% showed high-level resistance (>16 mg/liter). These isolates belonged to RT001 (7 of 22), RT017 (2 of 7), RT027 (4 of 22), and RT356 (2 of 4). There was location clustering in RT001, with 3 linezolid-resistant isolates from the same geographical location. These isolates also showed resistance to clindamycin and in some cases chloramphenicol (Table 2). A recent publication also described linezolid resistance among RT001, RT078, RT126, and RT017 isolates from Spain (11). The authors demonstrated the presence of the multi-drug resistance gene, *cfr*, in isolates showing high-level resistance to chloramphenicol, erythromycin, clindamycin, and linezolid from RT017, RT078, and RT126. This was linked to a mobile genetic element, Tn6218, indicating the possibility of transmission between strains. They were unable to demonstrate the presence of *cfr* in the remaining RT001 isolates that showed lower chloramphenicol MICs, suggesting that other resistance mechanisms are involved (11). There is likely to be more than one etiology for the linezolid resistance seen in the isolates tested here, given the phenotypes displayed. It is interesting to note that all of the linezolid-resistant isolates also displayed moxifloxacin resistance. This combination was associated with higher cadazolid MICs (2- to 4-fold higher than those of susceptible isolates with resistance to either moxifloxacin or linezolid) (12) and may not be unexpected since cadazolid is an oxazolidinone-fluoroquinolone hybrid molecule. However, its clinical significance is unknown, given the high fecal cadazolid concentrations achieved (13).

Only 6% of isolates were susceptible to ceftriaxone (GM MIC of 58.2 mg/liter) according to the breakpoints used (14). The highest levels of resistance (>128 mg/liter) were seen in RT356 isolates (all) and in 5 of 10 RT018 isolates, which are closely related. Ribotype 356 is exclusive to Italy, and all 5 RT018 isolates showing MICs of >128 mg/liter were also from this location. This high-level ceftriaxone resistance adds to the previously reported multi-drug resistance in RT018 and RT356 isolates from Italy (5). Two of the RT356 isolates also showed intermediate imipenem resistance (Table 2).

In summary, SMT19969 was highly active against more than 100 isolates displaying different antimicrobial resistance phenotypes. There was no evidence of SMT19969 or fidaxomicin resis-

tance, but some evidence of modestly higher SMT19969 and fidaxomicin MICs among ribotypes previously noted for multiple antimicrobial resistance. Linezolid resistance was more prevalent than expected and was also associated with ribotypes noted for multidrug resistance phenotypes. High-level ceftriaxone resistance was found in multiresistant RT018 and RT356 isolates from Italy.

ACKNOWLEDGMENTS

We are grateful to Chris Longshaw and Astellas Pharma Europe for permission to use *C. difficile* isolates collected as part of The ClosER Study.

R.V. is an employee of Summit plc and was involved in study design and manuscript preparation. J.F. has received research funding from Summit plc and Astellas Pharma Europe. M.H.W. has received research funding/consultancy/honoraria from Abbott, Actelion, Astellas, AstraZeneca, Bayer, Cerexa, Subist, Durata, The European Tissue Symposium, The Medicines Company, MedImmune, Merck, Motif Biosciences, Nabriva, Optimer, Paratek, Pfizer, Roche, Sanofi-Pasteur, Seres, Summit, Synthetics Biologics, bioMérieux, and Da Volterra. J.V. declares no conflicts of interest.

FUNDING INFORMATION

SUMMIT plc provided funding to Jane Freeman and Mark Wilcox under grant number MB14/11296.

Richard Vickers is an employee of Summit plc and was involved in study design and manuscript preparation.

REFERENCES

1. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. 2012. Clinical and economic burden of *Clostridium difficile* infection in Europe: a systematic review of healthcare-facility-acquired infection. *J Hosp Infect* 81:1–14. <http://dx.doi.org/10.1016/j.jhin.2012.02.004>.
2. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM, Young VB. 2008. Decreased diversity of the fecal microbiome in recurrent *Clostridium difficile*-associated diarrhea. *J Infect Dis* 197:435–438. <http://dx.doi.org/10.1086/525047>.
3. Corbett D, Wise A, Birchall S, Warn P, Baines SD, Crowther G, Freeman J, Chilton CH, Vernon J, Wilcox MH, Vickers RJ. 2015. In vitro susceptibility of *Clostridium difficile* to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against *C. difficile*. *J Antimicrob Chemother* 70:1751–1756. <http://dx.doi.org/10.1093/jac/dkv006>.
4. Goldstein EJ, Citron DM, Tyrrekk KL, Merriam CV. 2013. Comparative *in vitro* activities of SMT19969, a new antimicrobial agent, against *Clostridium difficile* and 350 Gram-positive and Gram negative aerobic and anaerobic intestinal flora isolates. *Antimicrob Agents Chemother* 57:4872–4876. <http://dx.doi.org/10.1128/AAC.01136-13>.
5. Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, Wilcox MH. 2015. Pan-European longitudinal surveillance of antimicrobial resistance among prevalent *Clostridium difficile* ribotypes. *Clin Microbiol Infect* 21:248.e9–248.e16. <http://dx.doi.org/10.1016/j.cmi.2014.09.017>.
6. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastantonio P, Kuijper EJ, Wilcox MH. 2008. Emergence of reduced susceptibility to metronidazole in *Clostridium difficile*. *J Antimicrob Chemother* 62:1046–1052. <http://dx.doi.org/10.1093/jac/dkn313>.
7. Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ, ECDIS Study Group. 2013. Antimicrobial activity of LFF571 and three treatment agents against *Clostridium difficile* isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. *J Antimicrob Chemother* 68:1305–1311. <http://dx.doi.org/10.1093/jac/dkt013>.
8. Goldstein EJC, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. 2011. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence and failure from patients in two phase III trials of fidaxomicin against *Clostridium difficile* infection. *Antimicrob Agents Chemother* 55:5194–5199. <http://dx.doi.org/10.1128/AAC.00625-11>.

TABLE 2 High-level resistance to linezolid among PCR ribotypes 001, 017, 027, and 356

Ribotype	SMT19969	Fidaxomicin	Metronidazole	Vancomycin	Rifampin	Moxifloxacin	Clindamycin	Imipenem	Chloramphenicol	Tigecycline	Linezolid	Ceftriaxone
001	0.06	0.15	1	0.5	0.002	32 ^a	128 ^a	2	256 ^a	0.03	16	64 ^a
001	0.03	0.008	1	0.5	0.001	16 ^a	128 ^a	8 ^b	16 ^b	0.03	32 ^a	128 ^a
001	0.06	0.015	1	2	0.002	16 ^a	64 ^a	4	32 ^a	0.03	32 ^a	128 ^a
001	0.125	0.008	0.5	0.5	0.002	16 ^a	128 ^a	4	16 ^b	0.03	32 ^a	128 ^a
001	0.125	0.008	1	0.5	0.002	16 ^a	128 ^a	4	16 ^b	0.03	32 ^a	128 ^a
001	0.125	0.008	1	0.5	0.002	16 ^a	128 ^a	2	16 ^b	0.03	32 ^a	128 ^a
001	0.06	0.008	1	0.5	0.002	16 ^a	128 ^a	4	16 ^b	0.03	32 ^a	64 ^a
017	0.125	0.06	0.25	0.5	0.001	32 ^a	128 ^a	4	16 ^b	0.06	32 ^a	32 ^b
017	0.25	0.06	0.125	0.5	32 ^a	32 ^a	128 ^a	4	64 ^a	0.06	32 ^a	64 ^a
027	0.06	0.06	1	1	32 ^a	16 ^a	8 ^a	8 ^b	4	0.03	16 ^a	128 ^a
027	0.06	0.06	1	1	32 ^a	16 ^a	8 ^a	8 ^b	4	0.03	16 ^a	128 ^a
027	0.25	0.06	1	1	32 ^a	32 ^a	8 ^a	8 ^b	4	0.03	16 ^a	64 ^a
027	0.25	0.06	1	0.5	32 ^a	32 ^a	128 ^a	4	64 ^a	0.03	32 ^a	128 ^a
027	0.25	0.125	1	0.5	0.002	32 ^a	128 ^a	4	64 ^a	0.03	32 ^a	64 ^a
356	0.03	0.06	1	1	32 ^a	32 ^a	8 ^a	8 ^b	4	0.03	16 ^a	256 ^a
356	0.06	0.06	0.5	2	32 ^a	32 ^a	16 ^a	8 ^b	8	0.03	16 ^a	256 ^a

^a Isolate that is resistant.
^b Isolate that is intermediate.

9. Vickers R, Robinson N, Best E, Echols R, Tillotson G, Wilcox M. 2015. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for *Clostridium difficile* infections. *BMC Infect Dis* 15:91. <http://dx.doi.org/10.1186/s12879-015-0759-5>.
10. Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. 2012. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with *Clostridium difficile* infection. *Clin Infect Dis* 55(Suppl 2):S116–S120. <http://dx.doi.org/10.1093/cid/cis337>.
11. Marín M, Martín A, Alcalá L, Cercenado E, Iglesias C, Reigadas E, Bouza E. 2015. *Clostridium difficile* isolates with high linezolid MICs harbour the multiresistance gene, *cfr*. *Antimicrob Agents Chemother* 59:586–589. <http://dx.doi.org/10.1128/AAC.04082-14>.
12. Locher HH, Seiler P, Chen X, Scroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, Kelly CP, Keck W. 2014. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of *Clostridium difficile* infection. *Antimicrob Agents Chemother* 58:892–900. <http://dx.doi.org/10.1128/AAC.01830-13>.
13. Mackie AE, Desnica B, Nicolas LB, Louie T, Dingemans J. 2013. Cadazolid, a novel potent antibiotic: minimal systemic cadazolid exposure in subjects with *Clostridium difficile* associated diarrhea, abstr. A-008. Abstr 53rd Intersci Conf Antimicrob Agents Chemother, Denver, CO.
14. Büchler AC, Rampini SK, Stelling S, Ledergerber B, Peter S, Schweiger A, Ruef C, Sbinden R, Speck RF. 2014. Antibiotic susceptibility of *Clostridium difficile* is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. *BMC Infect Dis* 14:607. <http://dx.doi.org/10.1186/s12879-014-0607-z>.